Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

CoVigilAI is a cutting-edge solution for monitoring medical literature that leverages artificial intelligence and sophisticated data analysis to identify and manage adverse drug reactions proactively, thereby safeguarding patient well-being and adhering to regulatory standards in real time. This platform simplifies the tracking of scientific and medical literature by sourcing information from major global databases like PubMed and Embase, offering customizable search parameters that enhance the pharmacovigilance literature review process. Additionally, it systematically reviews scientific articles and publications from various local journals, ensuring comprehensive global and localized literature oversight. Utilizing advanced algorithms, the system classifies Individual Case Safety Reports (ICSRs) into three categories: valid, potential, and invalid cases, while its automated key entity recognition capability adeptly identifies essential elements such as patients, medications, adverse reactions, and relevant medical events. This holistic approach not only streamlines the monitoring process but also significantly enhances the accuracy and efficiency of drug safety assessments.

Description

MEDLINE serves as the flagship bibliographic database of the National Library of Medicine (NLM), boasting over 29 million references to journal articles primarily focused on life sciences and biomedicine. One of the unique aspects of MEDLINE is its use of NLM Medical Subject Headings (MeSH) for indexing records, which enhances searchability and organization. It plays a crucial role as the foundational component of PubMed, a comprehensive literature database managed by the NLM's National Center for Biotechnology Information (NCBI). MEDLINE is essentially the digital evolution of the MEDical Literature Analysis and Retrieval System (MEDLARS), which was established in 1964. The selection of journals for inclusion in MEDLINE largely relies on the recommendations made by the Literature Selection Technical Review Committee (LSTRC), which comprises external experts appointed by the NIH. The database encompasses literature published from 1966 to the present day, alongside select works from earlier years, thereby providing a rich historical context for researchers. Overall, MEDLINE stands as a critical resource for professionals seeking reliable and organized biomedical literature.

API Access

Has API

API Access

Has API

Screenshots View All

Screenshots View All

Integrations

AWS Marketplace
Clarium Astra OS
Compier Literature Screening
ConnectPointz
ElevateHT
Embase
PubMed
SNF Metrics

Integrations

AWS Marketplace
Clarium Astra OS
Compier Literature Screening
ConnectPointz
ElevateHT
Embase
PubMed
SNF Metrics

Pricing Details

No price information available.
Free Trial
Free Version

Pricing Details

No price information available.
Free Trial
Free Version

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Vendor Details

Company Name

CoVigilAI

Country

India

Website

covigilai.in/

Vendor Details

Company Name

National Library of Medicine

Country

United States

Website

www.nlm.nih.gov/medline/medline_overview.html

Product Features

Product Features

Alternatives

Alternatives

Embase Reviews

Embase

Elsevier
Dialog Reviews

Dialog

Clarivate
Dialog Reviews

Dialog

Clarivate
Compier Literature Screening Reviews

Compier Literature Screening

Techsol Life Sciences